What it's sold for

Visceral fat loss
Anti-aging
Cognition

What has actually been tested

Abdominal Obesity
HIV
Mild Cognitive Impairment
Aging
Growth Hormone Deficiency
HIV Infections
HIV Lipodystrophy
Lipodystrophy

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Studied Visceral fat loss

Not listed Anti-aging

Studied Cognition

Every trial on record

Every registered human study we can find for Tesamorelin. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial ID	Title	Condition	Phase	Status	Enrolled
NCT07481734	Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)	Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis	Phase 2	Recruiting now	120
NCT03150511	Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury	Peripheral Nerve Injuries	Phase 2	Recruiting now	36
NCT06554717	Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV	HIV-1-infection, Frailty	Phase 2	Recruiting now	100
NCT00608023	TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy	Lipodystrophy, HIV Infections	Phase 3	Completed	263
NCT02553603	The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment	Mild Cognitive Impairment	Phase 1	Completed	22
NCT00675506	Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese	Abdominal Obesity, Growth Hormone Deficiency	Phase 2	Completed	60
NCT01264497	Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes	Type 2 Diabetes	Phase 2	Completed	55
NCT00850564	Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men	Healthy Volunteers	Not phased	Completed	15
NCT00257712	SMART: Somatotrophics, Memory, and Aging Research Trial	Aging, Mild Cognitive Impairment	Phase 2	Completed	151
NCT02012556	Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients	HIV	Phase 1	Completed	18
NCT03375788	Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk	Non-Alcoholic Fatty Liver Disease, Obesity	Phase 2	Completed	51
NCT00123253	TH9507 in Patients With HIV-Associated Lipodystrophy	HIV Infections, Lipodystrophy	Phase 3	Completed	412
NCT01263717	Effects of Growth Hormone Releasing Hormone in HIV	HIV, HIV Lipodystrophy	Not phased	Completed	54
NCT00795210	Effects of Short-term Growth Hormone in HIV-infected Patients	HIV Lipodystrophy	Not phased	Completed	25
NCT02196831	Tesamorelin Effects on Liver Fat and Histology in HIV	Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD)	Not phased	Completed	61
NCT02572323	Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons	Mild Cognitive Impairment	Phase 2	Completed	73
NCT03226821	Body Composition and Adipose Tissue in HIV	HIV Lipodystrophy Syndrome, Growth Hormone Deficiency	Phase 4	Stopped early	6
NCT01591902	Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®	Diabetic Retinopathy, HIV	Phase 4	Stopped early	129
NCT01388920	Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting	Chronic Obstructive Pulmonary Disease (COPD)	Phase 2	Stopped early	3
NCT01632592	Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue	Abdominal Obesity	Not phased	Withdrawn before enrolling	0 — nobody enrolled
NCT02931474	Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia	Sleep Disorder, Traumatic Brain Injury	Phase 2	Withdrawn before enrolling	0 — nobody enrolled

—Read this

A trial count is not a verdict

These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Common questions about Tesamorelin

How many human trials does Tesamorelin have?

21. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Tesamorelin FDA approved?

Yes, but read the detail: FDA-approved for HIV-associated lipodystrophy. An approval for one condition is not an approval for everything it is marketed for.

What is Tesamorelin actually being tested for?

Registered studies cover: metabolic associated steatotic liver disease, nonalcoholic steatohepatitis, hepatic steatosis. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.